The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation

Blood

Volumn 116, Issue 12, 2010, Pages 2164-2172

  Knight, Andrea ^a,b   Madrigal, Alejandro J ^a   Grace, Sarah ^b   Sivakumaran, Janani ^b   Kottaridis, Panagiotis ^b   Mackinnon, Stephen ^b   Travers, Paul J ^a,c   Lowdell, Mark W ^b  

^a ANTHONY NOLAN RESEARCH INSTITUTE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; T LYMPHOCYTE RECEPTOR DELTA CHAIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIRUS REACTIVATION; ALLOTRANSPLANTATION; CELL PROLIFERATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; VIRUS ACTIVATION; YOUNG ADULT;

ADOLESCENT; ADULT; CELL PROLIFERATION; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION; YOUNG ADULT;

EID: 77957197091     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-255166     Document Type: Article

References (50)

1. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95(7):2240-2245.
2. Craddock C, Szydlo RM, Dazzi F, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol. 2001;112(1):228-236. (Pubitemid 32151176)
3. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood. 2004;104(12):3664-3671. (Pubitemid 39564443)
4. Gillespie GM, Wills MR, Appay V, et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol. 2000;74(17):8140-8150.
5. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood. 2003;101(7):2686-2692.
6. Wang EC, Moss PA, Frodsham P, Lehner PJ, Bell JI, Borysiewicz LK. CD8highCD57+ T lymphocytes in normal, healthy individuals are oligoclonal and respond to human cytomegalovirus. J Immunol. 1995;155(10):5046-5056. (Pubitemid 3010847)
7. Weekes MP, Wills MR, Mynard K, Hicks R, Sissons JG, Carmichael AJ. Large clonal expansions of human virus-specific memory cytotoxic T lymphocytes within the CD57+ CD28- CD8+ T-cell population. Immunology. 1999;98(3):443-449.
8. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4(12):725-738. (Pubitemid 39574344)
9. Kunzmann V, Wilhelm M. Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma. 2005;46(5):671-680.
10. Pennington DJ, Silva-Santos B, Silberzahn T, et al. Early events in the thymus affect the balance of effector and regulatory T cells. Nature. 2006;444(7122):1073-1077. (Pubitemid 46018527)
11. Pennington DJ, Silva-Santos B, Hayday AC. Gammadelta T cell development: having the strength to get there. Curr Opin Immunol. 2005;17(2):108-115.
12. Xiong N, Raulet DH. Development and selection of gammadelta T cells. Immunol Rev. 2007;215:15-31.
13. Kaufmann SH. Gamma/delta and other unconventional T lymphocytes: what do they see and what do they do? Proc Natl Acad Sci U S A. 1996;93(6):2272-2279.
14. Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000;18:975-1026.
15. Carding SR, Egan PJ. Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol. 2002;2(5):336-345.
16. Poggi A, Venturino C, Catellani S, et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res. 2004;64(24):9172-9179.
17. Catellani S, Poggi A, Bruzzone A, et al. Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood. 2007;109(5):2078-2085.
18. Langerak AW, Wolvers-Tettero IL, van den Beemd MW, et al. Immunophenotypic and immunogenotypic characteristics of TCRgammadelta+ T cell acute lymphoblastic leukemia. Leukemia. 1999;13(2):206-214.
19. Marten A, von Lilienfeld-Toal M, Buchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer. 2006;119(10):2359-2365.
20. Zhao J, Huang J, Chen H, Cui L, He W. Vdelta1 T cell receptor binds specifically to MHC I chain related A: molecular and biochemical evidences. Biochem Biophys Res Commun. 2006;339(1):232-240.
21. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102(4):1389-1396.
22. Das H, Groh V, Kuijl C, et al. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity. 2001;15(1):83-93.
23. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14(2):123-133.
24. Sutherland CL, Rabinovich B, Chalupny NJ, Brawand P, Miller R, Cosman D. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood. 2006;108(4):1313-1319. (Pubitemid 44232030)
25. Eberl M, Jomaa H, Hayday AC. Integrated immune responses to infection: cross-talk between human gammadelta T cells and dendritic cells. Immunology. 2004;112(3):364-368. (Pubitemid 38859513)
26. Das H, Wang L, Kamath A, Bukowski JF. Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood. 2001;98(5):1616-1618.
27. Dechanet J, Merville P, Lim A, et al. Implication of gammadelta T cells in the human immune response to cytomegalovirus. J Clin Invest. 1999;103(10):1437-1449.
28. Halary F, Pitard V, Dlubek D, et al. Shared reactivity of Vδ2(neg) γδ T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med. 2005;201(10):1567-1578.
29. Lafarge X, Merville P, Cazin MC, et al. Cytomegalovirus infection in transplant recipients resolves when circulating gammadelta T lymphocytes expand, suggesting a protective antiviral role. J Infect Dis. 2001;184(5):533-541.
30. Pitard V, Roumanes D, Lafarge X, et al. Long term expansion of effector/memory Vδ2neg γδ T cells is a specific blood signature of CMV infection. Blood. 2008;112(4):1317-1324.
31. Couzi L, Levaillant Y, Jamai A, et al. Cytomegalovirus-induced γδ T cells associate with reduced cancer risk after kidney transplantation. J Am Soc Nephrol. 2010;21(1):181-188.
32. Mattes FM, Hainsworth EG, Hassan-Walker AF, et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis. 2005;191(1):89-92.
33. Vermijlen D, Brouwer M, Donner C, et al. Human cytomegalovirus elicits fetal γδ T cell responses in utero. J Exp Med. 2010;207(4):807-821.
34. North J, Bakhsh I, Marden C, et al. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J Immunol. 2007;178(1):85-94. (Pubitemid 46033590)
35. De Rosa SC, Herzenberg LA, Herzenberg LA, Roederer M. 11-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity. Nat Med. 2001;7(2):245-248. (Pubitemid 32148494)
36. Poccia F, Agrati C, Martini F, Capobianchi MR, Wallace M, Malkovsky M. Antiviral reactivities of gammadelta T cells. Microbes Infect. 2005;7(3):518-528.
37. Rossol R, Dobmeyer JM, Dobmeyer TS, et al. Increase in Vdelta1+ gammadelta T cells in the peripheral blood and bone marrow as a selective feature of HIV-1 but not other virus infections. Br J Haematol. 1998;100(4):728-734.
38. Poggi A, Carosio R, Fenoglio D, et al. Migration of V delta 1 and V delta 2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1-infected patients: competition by HIV-1 Tat. Blood. 2004;103(6):2205-2213.
39. Poccia F, Gougeon ML, Agrati C, et al. Innate T-cell immunity in HIV infection: the role of Vgamma9Vdelta2 T lymphocytes. Curr Mol Med. 2002;2(8):769-781.
40. Hyjek EM, Bartkowiak J, Drozdz R, et al. Evidence for B cell-mediated activation of V delta 1+ T lymphocytes during progression of HIV infection. J Immunol. 1997;158(1):464-474.
41. Orsini DL, Res PC, Van Laar JM, et al. A subset of V delta 1+ T cells proliferates in response to Epstein-Barr virus-transformed B cell lines in vitro. Scand J Immunol. 1993;38(4):335-340.
42. Orsini DL, van Gils M, Kooy YM, et al. Functional and molecular characterization of B cell-responsive V delta 1+ gamma delta T cells. Eur J Immunol. 1994;24(12):3199-3204.
43. Cela ME, Holladay MS, Rooney CM, et al. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant. 1996;17(2):243-247.
44. Hirokawa M, Horiuchi T, Kawabata Y, Kitabayashi A, Miura AB. Reconstitution of gammadelta T cell repertoire diversity after human allogeneic hematopoietic cell transplantation and the role of peripheral expansion of mature T cell population in the graft. Bone Marrow Transplant. 2000;26(2):177-185.
45. Fujishima N, Hirokawa M, Fujishima M, et al. Skewed T cell receptor repertoire of Vdelta1(+) gammadelta T lymphocytes after human allogeneic haematopoietic stem cell transplantation and the potential role for Epstein-Barr virus-infected B cells in clonal restriction. Clin Exp Immunol. 2007;149(1):70-79.
46. Boullier S, Cochet M, Poccia F, Gougeon ML. CDR3-independent gamma delta V delta 1+ T cell expansion in the peripheral blood of HIV-infected persons. J Immunol. 1995;154(3):1418-1431.
47. Agrati C, D'Offizi G, Narciso P, et al. Vdelta1 T lymphocytes expressing a Th1 phenotype are the major gammadelta T-cell subset infiltrating the liver of HCV-infected persons. Mol Med. 2001;7(1):11-19.
48. Jouen-Beades F, Halary F, Drouot L, et al. Expansion of circulating V gamma 9/V delta 1 T cells in a patient with a syndrome of recurrent fever: evidence for an unusual antigen-driven process leading to selection of recurrent motifs within TCR junctional loops of diverse lengths. Eur J Immunol. 1999;29(10):3338-3349.
49. Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis. 2008;40(1):63-67. (Pubitemid 350192302)
50. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362(9393):1375-1377. (Pubitemid 37338339)